Extended Release Medications in Opioid Use Disorders-View Presentation

Video Transcription

Video Summary

The video content is a presentation by Dr. Soraya Azari about the use of long-acting injectables for the treatment of opioid use disorder (OUD). Dr. Azari discusses the pharmacokinetics of buprenorphine extended-release (Bup-XR), also known as Sublocade, and its use in OUD treatment. She explains that Bup-XR is given as a monthly subcutaneous injection and provides a controlled release of buprenorphine in the body. Dr. Azari also mentions another long-acting agent, injectable naltrexone (XR naltrexone or Vivitrol), which is approved for the treatment of OUD and alcohol use disorder.<br /><br />The presentation highlights the evidence base for Bup-XR, including its comparison to Bup-sublingual. Dr. Azari mentions studies showing that Bup-XR has a slightly higher rate of opioid-negative urine toxicology screens compared to Bup-sublingual, but overall outcomes are similar. She also discusses the use of Bup-XR in high-risk populations, such as individuals with a history of overdose, and the potential for Bup-XR to protect against fentanyl-induced respiratory depression. Dr. Azari notes the challenges and considerations for starting patients on XR naltrexone and the need for further research in this area.<br /><br />Overall, the presentation provides an overview of the use of long-acting injectables for OUD treatment, focusing on Bup-XR and XR naltrexone. The information is presented in a clear and concise manner, summarizing key points and highlighting the current evidence.

Keywords

long-acting injectables

opioid use disorder

Bup-XR

Sublocade

pharmacokinetics

injectable naltrexone

Vivitrol

evidence base

Bup-sublingual